Kimberly Hess
Research Subjects
Kimberly Hess has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Roger Bate
American Enterprise Institute
3 shared publications - Richard Tren
Africa Fighting Malaria, Washington, DC
2 shared publications - Amir Attaran
University of Ottawa
1 shared publication
Latest Publications
- Open Access
- 11 June 2010
- Published by Springer Nature in Malaria Journal
- Vol. 9 (1) , 157
Anti-malarial drug quality in Lagos and Accra - a comparison of various quality assessments
Two major cities in West Africa, Accra, the capital of Ghana, and Lagos, the largest city of Nigeria, have significant problems with substandard pharmaceuticals. Both have actively combated the problem in recent years, particularly by screening products on the market using the Global Pharma Health Fund e.V. Minilab® protocol. Random sampling of medicines from the two cities at least twice over the past 30 months allows a tentative assessment of whether improvements in drug quality have occurred. Since intelligence provided by investigators indicates that some counterfeit producers may be adapting products to pass Minilab tests, the results are compared with those from a Raman spectrometer and discrepancies are discussed.
- 11 June 2010
- Published by Springer Nature in Malaria Journal
- Vol. 9 (1) , 157
Open AccessAnti-malarial drug quality in Lagos and Accra - a comparison of various quality assessments
Two major cities in West Africa, Accra, the capital of Ghana, and Lagos, the largest city of Nigeria, have significant problems with substandard pharmaceuticals. Both have actively combated the problem in recent years, particularly by screening products on the market using the Global Pharma Health Fund e.V. Minilab® protocol. Random sampling of medicines from the two cities at least twice over the past 30 months allows a tentative assessment of whether improvements in drug quality have occurred. Since intelligence provided by investigators indicates that some counterfeit producers may be adapting products to pass Minilab tests, the results are compared with those from a Raman spectrometer and discrepancies are discussed.
- Open Access
- 22 December 2009
- Published by Springer Nature in Malaria Journal
- Vol. 8 (1) , 305
Drug procurement, the Global Fund and misguided competition policies
In an effort to increase competition and decrease price, the Global Fund to Fight AIDS, Tuberculosis and Malaria recently began asking some grant recipients to use international competitive bidding processes for certain drug purchases. Unfortunately, for countries like Kenya, this request has caused more harm than good. After awarding the tender for its annual supply of the anti-malarial artemether-lumefantrine to the lowest bidder, Ajanta Pharma, Kenya experienced wide stock-outs in part due to the company's inability to supply the order in full and on time. Similar problems could arise in Uganda. Despite Kenya's experience, Uganda has awarded its next tender for artemether-lumefantrine to Ajanta Pharma. Uganda is already facing wide stock-outs and risks exacerbating an already dire situation the longer it takes to fulfil the procurement contract. A tender process based primarily on price cannot account for a company's ability to consistently supply sufficient product in time.
- 22 December 2009
- Published by Springer Nature in Malaria Journal
- Vol. 8 (1) , 305
Open AccessDrug procurement, the Global Fund and misguided competition policies
In an effort to increase competition and decrease price, the Global Fund to Fight AIDS, Tuberculosis and Malaria recently began asking some grant recipients to use international competitive bidding processes for certain drug purchases. Unfortunately, for countries like Kenya, this request has caused more harm than good. After awarding the tender for its annual supply of the anti-malarial artemether-lumefantrine to the lowest bidder, Ajanta Pharma, Kenya experienced wide stock-outs in part due to the company's inability to supply the order in full and on time. Similar problems could arise in Uganda. Despite Kenya's experience, Uganda has awarded its next tender for artemether-lumefantrine to Ajanta Pharma. Uganda is already facing wide stock-outs and risks exacerbating an already dire situation the longer it takes to fulfil the procurement contract. A tender process based primarily on price cannot account for a company's ability to consistently supply sufficient product in time.
- Open Access
- 25 February 2009
- Published by Springer Nature in Malaria Journal
- Vol. 8 (1) , 33
Physical and chemical stability of expired fixed dose combination artemether-lumefantrine in uncontrolled tropical conditions
New artemisinin combination therapies pose difficulties of implementation in developing and tropical settings because they have a short shelf-life (two years) relative to the medicines they replace. This limits the reliability and cost of treatment, and the acceptability of this treatment to health care workers. A multi-pronged investigation was made into the chemical and physical stability of fixed dose combination artemether-lumefantrine (FDC-ALU) stored under heterogeneous, uncontrolled African conditions, to probe if a shelf-life extension might be possible.
- 25 February 2009
- Published by Springer Nature in Malaria Journal
- Vol. 8 (1) , 33
Open AccessPhysical and chemical stability of expired fixed dose combination artemether-lumefantrine in uncontrolled tropical conditions
New artemisinin combination therapies pose difficulties of implementation in developing and tropical settings because they have a short shelf-life (two years) relative to the medicines they replace. This limits the reliability and cost of treatment, and the acceptability of this treatment to health care workers. A multi-pronged investigation was made into the chemical and physical stability of fixed dose combination artemether-lumefantrine (FDC-ALU) stored under heterogeneous, uncontrolled African conditions, to probe if a shelf-life extension might be possible.